Alzheimer’s Gene CASS4 Shows Potential as Therapeutic Target

Researchers have identified vulnerabilities in a gene linked to Alzheimer’s disease that hinder the brain’s immune cells in managing harmful protein build-up. This discovery provides a potential new target for therapies aiming to slow Alzheimer’s progression, based on a recent study conducted on mice.

John Lukens, director of the University of Virginia’s Harrison Family Translational Research Center, stated that the gene, CASS4, is a significant Alzheimer’s risk gene, yet its overall impact on brain health was previously not well understood. “Our work demonstrates that CASS4 helps microglia to manage neurotoxic amyloid beta aggregates. Its absence may lead to increased amyloid plaque spread, neuronal damage, and cognitive decline,” Lukens stated.

The Role of CASS4 in Brain Health

The study’s findings are preliminary and based on laboratory mice. It remains uncertain if targeting CASS4 in human patients, particularly those in early disease stages, will yield similar results. Understanding CASS4’s interaction with microglia could introduce new strategies to curb Alzheimer’s disease progression.

The Brain’s Cleanup System

Alzheimer’s disease involves the build-up of sticky amyloid-beta plaques and tangled tau proteins in the brain. Microglia play a key role in the brain’s reaction to this damage. When functioning correctly, microglia create barriers around amyloid-beta plaques, limiting potential harm.

The research led by Lukens delved into the CASS4 gene, identified as an Alzheimer’s risk factor. They discovered CASS4 regulates microglia’s reaction to harmful plaques. Disruption of CASS4 in mice led to less effective microglia, aggressive plaque spread, neuron damage, and cognitive decline. This disruption also affected gene activity, possibly impacting other neurodegenerative diseases like Parkinson’s disease.

First study author Addie Walsh stated: “These findings provide new insights into how CASS4 functions in the brain, suggesting it helps microglia respond to amyloid pathologies.”

Potential for New Treatments

Researchers propose therapies to enhance CASS4 activity in microglia as a method to limit Alzheimer’s progression. “Our work suggests promoting CASS4 function in microglia could offer a new strategy to slow down Alzheimer’s disease,” stated Lukens. The team also seeks to explore CASS4’s role in other diseases like Parkinson’s, ALS, and multiple sclerosis, and is keen to develop drugs targeting CASS4 for future clinical trials.

However, experts urge caution as these results in mice are early steps in treatment development. Behavioral neurologist Dr. James Bateman noted, “Knocking out CASS4 in mice results in faulty microglia and impaired plaque clearance. Preclinical findings are vital but there’s a long journey from these findings to potential therapies.”

Reference: Lukens, J. R., Walsh, A. E. et al. (2026). Alzheimer’s genetic risk factor CASS4 controls microglial focal adhesion biology and amyloidosis. Journal of Experimental Medicine.